Treatment patterns of patients with HR+/HER2- metastatic breast cancer receiving CDK4/6 inhibitor-based regimens: a cohort study in the French nationwide healthcare database

被引：0
|
作者：
Stephanie H. Read
Nadia Quignot
Raissa Kapso-Kapnang
Erin Comerford
Ying Zheng
Corona Gainford
Medha Sasane
Anne-Lise Vataire
Laure Delzongle
Francois-Clement Bidard
机构：
[1] Certara UK Limited,Department of Medical Oncology
[2] Certara France,undefined
[3] Sanofi,undefined
[4] Sanofi,undefined
[5] Institut Curie,undefined
[6] Université Versailles Saint-Quentin,undefined
[7] Université Paris-Saclay,undefined
来源：
Breast Cancer Research and Treatment | 2024年 / 204卷
关键词：
Hormone receptor negative; Metastatic breast cancer; Endocrine therapy; Cyclin-dependent kinase 4/6 inhibitor; Real-world evidence; SNDS;
D O I：
暂无
中图分类号：
学科分类号：
摘要：
引用
收藏
页码：579 / 588
页数：9
相关论文
共 50 条
  • [1] Treatment patterns of patients with HR+/HER2-metastatic breast cancer receiving CDK4/6 inhibitor-based regimens: a cohort study in the French nationwide healthcare database
    Read, Stephanie H.
    Quignot, Nadia
    Kapso-Kapnang, Raissa
    Comerford, Erin
    Zheng, Ying
    Gainford, Corona
    Sasane, Medha
    Vataire, Anne-Lise
    Delzongle, Laure
    Bidard, Francois-Clement
    BREAST CANCER RESEARCH AND TREATMENT, 2024, 204 (03) : 579 - 588
  • [2] Patients with HR+/HER2- metastatic breast cancer treated with CDK4/6 inhibitors: a real-world study in Italy
    Perrone, Valentina
    Dovizio, Melania
    Leogrande, Melania
    Tamma, Antonella
    Giovannitti, Massimo
    Buzzoni, Carlotta
    Esposti, Luca Degli
    BREAST CANCER MANAGEMENT, 2023, 12 (02)
  • [3] Advancing treatment choices: CDK4/6 inhibitor switching in HR+/HER2-metastatic breast cancer
    Zagami, Paola
    Esposito, Angela
    Salimbeni, Beatrice Taurelli
    Giachetti, Pier Paolo Maria Berton
    Scafetta, Roberta
    Lambertini, Matteo
    Di Maio, Massimo
    Curigliano, Giuseppe
    Criscitiello, Carmen
    Cinieri, Saverio
    BREAST, 2025, 79
  • [4] MONARCH 1, A Phase II Study of Abemaciclib, a CDK4 and CDK6 Inhibitor, as a Single Agent, in Patients with Refractory HR+/HER2- Metastatic Breast Cancer
    Dickler, Maura N.
    Tolaney, Sara M.
    Rugo, Hope S.
    Cortes, Javier
    Dieras, Veronique
    Patt, Debra
    Wildiers, Hans
    Hudis, Clifford A.
    O'Shaughnessy, Joyce
    Zamora, Esther
    Yardley, Denise A.
    Frenzel, Martin
    Koustenis, Andrew
    Baselga, Jose
    CLINICAL CANCER RESEARCH, 2017, 23 (17) : 5218 - 5224
  • [5] Shared Decision-Making on Using a CDK4/6 Inhibitor plus an Aromatase Inhibitor for HR+/HER2- Metastatic Breast Cancer: A Podcast
    Dong, Brian
    Lusen, Rita
    Chick, Ella
    Kline, Lisa
    ONCOLOGY AND THERAPY, 2023, 11 (04) : 411 - 418
  • [6] Advances in the mechanism of CDK4/6 inhibitor resistance in HR+/HER2-breast cancer
    Wu, Sijia
    Xu, Junnan
    Ma, Yiwen
    Liang, Guilian
    Wang, Jiaxing
    Sun, Tao
    THERAPEUTIC ADVANCES IN MEDICAL ONCOLOGY, 2024, 16
  • [7] Immune effects of CDK4/6 inhibitors in patients with HR+/HER2- metastatic breast cancer: Relief from immunosuppression is associated with clinical response
    Scirocchi, Fabio
    Scagnoli, Simone
    Botticelli, Andrea
    Di Filippo, Alessandra
    Napoletano, Chiara
    Zizzari, Ilaria Grazia
    Strigari, Lidia
    Tomao, Silverio
    Cortesi, Enrico
    Rughetti, Aurelia
    Marchetti, Paolo
    Nuti, Marianna
    EBIOMEDICINE, 2022, 79
  • [8] How to Treat HR+/HER2-Metastatic Breast Cancer Patients after CDK4/6 Inhibitors: An Unfinished Story
    Cogliati, Viola
    Capici, Serena
    Pepe, Francesca Fulvia
    di Mauro, Pierluigi
    Riva, Francesca
    Cicchiello, Federica
    Maggioni, Claudia
    Cordani, Nicoletta
    Cerrito, Maria Grazia
    Cazzaniga, Marina Elena
    LIFE-BASEL, 2022, 12 (03):
  • [9] Real-world treatment outcomes in HR+ HER2- metastatic breast cancer patients treated with CDK4/6 inhibitors: Results from a reference center in Brazil
    Queiroz, Marcello Moro
    Sacardo, Karina Perez
    Ribeiro, Mauricio Fernando
    Gadotti, Luiza Lara
    Saddi, Rodrigo
    Oliveira, Leandro Jonata de Carvalho
    Linck, Rudinei Diogo Marques
    Cruz, Marcelo Rocha de Souza
    Barroso-Sousa, Romualdo
    Sahade, Marina
    Correa, Tatiana Strava
    Mano, Max Senna
    Suzuki, Daniele Assad
    Shimada, Andrea Kazumi
    Katz, Artur
    CANCER TREATMENT AND RESEARCH COMMUNICATIONS, 2023, 35
  • [10] First-line CDK4/6 inhibitor-based combinations for HR+/HER2-advanced breast cancer: A Bayesian network meta-analysis
    Guo, Xianan
    Zhou, Yunxiang
    Zhang, Kun
    Lu, Wei
    Zhong, Xi
    Wu, Shijie
    Shen, Lu
    Chen, Huihui
    Chen, Yiding
    JOURNAL OF EVIDENCE BASED MEDICINE, 2024, 17 (01) : 106 - 118
12345